Use of beta-blockers has proven beneficial in patients with hypertension, heart failure, and in people who have suffered a heart attack. The use in patients who have Chronic Obstructive Pulmonary Disease (COPD) and reactive airway disease, however, has been limited due to possible side effects such as worsening of lung function or increasing airway spasms and asthma attacks. The purpose of this study is to find out if patients with COPD can tolerate being on a beta-blocker at doses recommended for the treatment of heart disease conditions. This study also seeks to find out if a selective beta-1 receptor beta-blocker is better than a non-selective beta-blocker in patients with mild to moderate COPD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Cardioselective beta-blocker
Non-cardioselective beta-blocker
VA West Los Angeles Medical Center
Los Angeles, California, United States
Percent Change in FEV1
Time frame: 0, 4, 8, 14, 18 weeks
Mean dose
Mean dose of beta-blocker achieved during low (weeks 0-4 and 10-14) and high (weeks 4-8, 14-18) treatment period
Time frame: 0-4, 4-8, 10-14, 14-18 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.